Find information about GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for health care professionals. Please see Important Safety Information on this website.

Dec 11, 2014 · GARDASIL 9 includes the greatest number of HPV types in any available HPV vaccine . Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved GARDASIL ® 9 (Human Papillomavirus 9-valent Vaccine,

Jan 28, 2025 · Merck is a defendant in product liability lawsuits in the United States involving GARDASIL ® (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and GARDASIL ® 9 (Human Papillomavirus 9-valent Vaccine, Recombinant).

GARDASIL 9 does not treat HPV infection, cancer, or genital warts. GARDASIL 9 is a shot that is usually given in the arm muscle. GARDASIL 9 may be given as 2 or 3 shots. For persons 9 through 14 years of age, GARDASIL 9 can be given using a 2-dose or 3-dose schedule.

Jun 12, 2020 · GARDASIL ® 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) Now Approved for the Prevention of HPV-Related Cervical, Vaginal, Vulvar, Anal, Oropharyngeal and Other Head and Neck Cancers

GARDASIL® is a vaccine indicated in girls and women 9 through26 years of age for the prevention of the following diseases caused by Human Papillomavirus (HPV) types included in the vaccine:

Mar 15, 2024 · Tradename: GARDASIL 9 Manufacturer: Merck Sharp & Dohme LLC Indications: Indicated in girls and women 9 through 45 years of age for the prevention of the following diseases:

The 9-valent HPV vaccine protects against HPV types 16 and 18, which cause about 66% of cervical cancers and most other HPV-attributable cancers in the United States, and five additional cancer-causing types, which account for about 15% of cervical cancers.

Tradename: Gardasil Manufacturer: Merck & Co., Inc. Indications: Prevention of vulvar and vaginal cancer

GARDASIL®9, Human Papillomavirus 9 -valent Vaccine, Recombinant, is a vaccine indicated in individuals 9 through 45 years of age for the prevention of infection caused by the Human Papillomavirus (HPV)

GARDASIL 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.

Review the dosing schedule for GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant), including information about the recommended regimen. Please see Important Safety Information on this website.

Mar 13, 2024 · Merck vaccine researchers continue to build on the development of GARDASIL and GARDASIL 9 to identify new candidates with the potential to extend protection against a broader array of HPV types. The latest addition to the pipeline employs the company’s proprietary virus-like particle (VLP) technology to incorporate additional VLPs for ...

4 days ago · The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country.

4 days ago · Overall sales of Gardasil fell 17% to $1.55 billion in the final quarter of last year, mainly due to the lower demand in China. Gardasil vaccine protects against cancer-causing human papilloma virus or HPV infections. The pause announcement comes a month after Merck received approval in China for use of the vaccine in males.

4 days ago · Merck's Gardasil sales fell short of expectations in the fourth quarter, and the company pulled its long-term target of $11 billion in Gardasil sales by 2030 in light of the decision to stop ...

GARDASIL 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.

3 days ago · Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US ...

Nov 12, 2024 · RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new clinical and real-world data for the company’s 9-valent Human Papillomavirus (HPV) vaccine, GARDASIL ® 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), evaluating the burden and incidence of …

4 days ago · Merck MRK-0.35% decrease; red down pointing triangle shares tumbled more than 11% Tuesday morning after the drugmaker gave 2025 revenue guidance that fell short of analyst expectations and said it ...

Mar 8, 2024 · Patients filed lawsuits, Charlotte’s U.S. District Court alleging medical issues triggered after receiving Merck’s HPV vaccination Gardasil.

4 days ago · Merck’s Gardasil sales fell short of expectations in the fourth quarter, and the company pulled its long-term target of $11 billion in Gardasil sales by 2030 in light of the decision to stop ...

Jan 1, 2025 · Gardasil® vaccine lawsuits are being filed claiming that Merck concealed the risks of autoimmune diseases and other long term side effects of Gardasil while falsely promoting the vaccine as a...

Jan 8, 2025 · GARDASIL is the first HPV vaccine approved for the prevention of certain HPV-related cancers and diseases in Chinese males Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the National Medical Products Administration (NMPA) of China approved GARDASIL ® [Human Papillomavirus Quadrivalent …

GARDASIL 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.

GARDASIL 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.